Egetis to commence a rolling NDA submission in December as granted by the FDA for Emcitate® (tiratricol)· Egetis received FDA Breakthrough Therapy Designation for Emcitate® (tiratricol) for MCT8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback